<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02891278</url>
  </required_header>
  <id_info>
    <org_study_id>AAAQ8444</org_study_id>
    <secondary_id>6474-15</secondary_id>
    <nct_id>NCT02891278</nct_id>
  </id_info>
  <brief_title>Sertraline and Cytosine Arabinoside in Adults With Relapsed and Refractory AML</brief_title>
  <official_title>The Clinical Application of Tumor Reversion: A Phase I Study of Sertraline (Zoloft) in Combination With Timed-sequential Cytosine Arabinoside (Ara-C) in Adults With Relapsed and Refractory Acute Myeloid Leukemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Leukemia and Lymphoma Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I study with the goals of determining the feasibility, safety, and toxicity&#xD;
      of administering sertraline in combination with timed-sequential cytosine arabinoside (ara-C)&#xD;
      in adults with relapsed and refractory acute myeloid leukemia (AML).&#xD;
&#xD;
      Primary objective:&#xD;
&#xD;
        -  To define the maximum tolerated dose (MTD) and Recommended Phase II Dose (RP2D) of&#xD;
           sertraline administered in combination with timed-sequential cytosine arabinoside in&#xD;
           adult patients with relapsed and refractory acute myeloid leukemia.&#xD;
&#xD;
        -  To evaluate the safety and tolerability of sertraline given in combination with&#xD;
           timed-sequential cytosine arabinoside in adult patients with relapsed and refractory&#xD;
           acute myeloid leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Relapsed and refractory acute myeloid leukemias are characterized by net drug resistance. At&#xD;
      the root of this drug resistance is an enhanced survival that relates to intrinsic cell cycle&#xD;
      dysregulation and aberrations in the overall process of the repair of DNA damage. These&#xD;
      malignancies represent a continuing therapeutic challenge, since currently no &quot;standard&#xD;
      treatments&quot; for these diseases exist. Approximately 30% of adults with newly diagnosed AML&#xD;
      are primary refractory to chemotherapy and at least 50% of those who achieve remission will&#xD;
      relapse. For patients with relapsed or refractory AML, the expected CR/CRi rates with&#xD;
      traditional multi-agent chemotherapies range from &lt; 10% for primary refractory AML to 25-30%&#xD;
      for relapsed AML and cure rates &lt; 20%, even with allogeneic stem cell transplantation. Thus,&#xD;
      novel treatment approaches are needed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 11, 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of sertraline administered in combination with timed-sequential cytosine arabinoside</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Standard 3+3 dose-escalation design will be used to determine the MTD. The MTD will be determined as the highest dose level where 1/6 patients experience dose-limiting toxicity (DLT). Three patients will be treated at a given dose level combination and observed for at least 4 weeks to assess toxicity. Doses will not be escalated in any individual patient.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Sertraline with cytosine arabinoside</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive the following:&#xD;
Induction phase&#xD;
Sertraline, twice daily at one of the pre-defined dose levels&#xD;
Cytosine arabinoside, on days 1 and 10&#xD;
Consolidation phase&#xD;
Patients who achieve complete remission (CR) or complete remission with incomplete count recovery (CRi) and are eligible for allogeneic stem cell transplantation will receive one of the following:&#xD;
Allogeneic SCT and off study&#xD;
Repeat cycle of oral sertraline and cytosine arabinoside IV infusion&#xD;
Maintenance phase with sertraline for cycles of 28 days in length</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertraline</intervention_name>
    <description>Sertraline is a selective serotonin reuptake inhibitor (SSRI) that is FDA approved to treat major depressive disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder, and social anxiety disorder.&#xD;
Sertraline will be administered orally twice a day starting on day -3. Sertraline will be administered at one of 4 pre-defined dose levels in the following dose-escalation: 50 mg daily, 50 mg twice a day, 50 mg every morning (QAM) and 100 mg every evening (QPM), 100 mg twice a day. 100 mg QAM and 150 mg QPM.</description>
    <arm_group_label>Sertraline with cytosine arabinoside</arm_group_label>
    <other_name>Zoloft</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytosine arabinoside</intervention_name>
    <description>Cytarabine is a cytotoxic chemotherapy approved for use in acute myeloid leukemia, acute lymphoblastic leukemia, and chronic myelogenous leukemia. It is also approved to prevent and treat meningeal leukemia. Cytarabine kills cells in S-phase through inhibition of DNA polymerase, as well as by halting DNA synthesis after its incorporation into DNA.&#xD;
Cytosine arabinoside (Ara-C) will be administered as a 72 hour intravenous continuous infusion (IVCI) beginning Day 1 of therapy and again beginning Day 10 of therapy. The total dose of ara-C for each 72 hour period is 2 gm/m2 (0.667 gm/m2/24 hours).</description>
    <arm_group_label>Sertraline with cytosine arabinoside</arm_group_label>
    <other_name>ara-C</other_name>
    <other_name>Cytarabine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic stem cell transplantation</intervention_name>
    <description>Allogeneic stem cell transplantation involves transferring the stem cells from a healthy person (the donor) to a patient after high-intensity chemotherapy or radiation.</description>
    <arm_group_label>Sertraline with cytosine arabinoside</arm_group_label>
    <other_name>allogeneic SCT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically-confirmed diagnoses of relapsed AML: Patients with AML that have&#xD;
             relapsed at least once or are primary induction failure will be eligible&#xD;
&#xD;
          -  Age ≥ 18 and ≤ 70 years&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0 - 2&#xD;
&#xD;
          -  ≥ 2 weeks off cytotoxic chemotherapy&#xD;
&#xD;
          -  ≥ 2 weeks off radiation therapy&#xD;
&#xD;
          -  Off biologic therapies including hematopoietic growth factors ≥ 1 week&#xD;
&#xD;
          -  If using tyrosine kinase inhibitors (TKIs)/src inhibitors, other non-cytotoxics, or&#xD;
             leukopheresis for blast count control, the patient must be off these therapies for &gt;&#xD;
             24 hrs before starting sertraline. Hydroxyurea will be allowed with sertraline but&#xD;
             should be stopped ≥24 hours before starting cytarabine.&#xD;
&#xD;
          -  Adequate organ function as defined below:&#xD;
&#xD;
               -  Renal function: Serum creatinine &lt;2.0 mg/dL or creatinine clearance ≥ 50&#xD;
                  mL/minute&#xD;
&#xD;
               -  Hepatic function: aspartate aminotransferase (AST), alanine aminotransferase&#xD;
                  (ALT) and Alkaline Phosphatase ≤ 5x Upper Limit normal (ULN), bilirubin ≤ 2.0&#xD;
                  mg/dl, unless due to Gilbert's, hemolysis or leukemic infiltration&#xD;
&#xD;
               -  Left Ventricular Ejection Fraction ≥ 45% by multigated acquisition (MUGA) scan or&#xD;
                  Echocardiogram&#xD;
&#xD;
          -  Patients who have undergone stem cell transplantation (SCT), autologous or allogeneic,&#xD;
             are eligible provided that they are ≥ 8 weeks from stem cell infusion, have no active&#xD;
             graft versus host disease (GVHD), are off immune suppression for at least 2 weeks, and&#xD;
             do not have a history of veno-occlusive disease (VOD)&#xD;
&#xD;
          -  Female patients of childbearing age must have negative pregnancy test and women of&#xD;
             child-bearing potential and men must agree to use adequate contraception (hormonal or&#xD;
             barrier method of birth control; abstinence) prior to study entry and for 30 days&#xD;
             after study participation&#xD;
&#xD;
          -  Patients must be able to give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concomitant chemotherapy, radiation therapy, or immunotherapy&#xD;
&#xD;
          -  Patients who are receiving any other investigational agents concurrently&#xD;
&#xD;
          -  Hyperleukocytosis with ≥ 30,000 blasts/microliter (uL). If using tyrosine kinase/src&#xD;
             inhibitors (FLT-3 inhibitors), other non-cytotoxics, or leukopheresis for blast count&#xD;
             control, the patient must be off these therapies for ≥ 24 hours prior to beginning&#xD;
             sertraline. If using hydroxyurea for blast count control, this may be continued until&#xD;
             up to 24 hours before starting cytarabine&#xD;
&#xD;
          -  Acute Progranulocytic Leukemia (APL)&#xD;
&#xD;
          -  Active central nervous system (CNS) leukemia&#xD;
&#xD;
          -  Active, uncontrolled infection. Patients with infection under active treatment and&#xD;
             controlled with antibiotics are eligible&#xD;
&#xD;
          -  Presence of other life-threatening illness&#xD;
&#xD;
          -  Patients with mental deficits and/or psychiatric history that preclude them from&#xD;
             giving informed consent or from following protocol&#xD;
&#xD;
          -  Pregnant women are excluded from this study due to potential teratogenic and/or&#xD;
             abortifacient effect of this combination chemotherapy. Nursing mother should stop&#xD;
             breastfeeding to be eligible due to potential risk for adverse events in nursing&#xD;
             infant&#xD;
&#xD;
          -  Subjects with the following cardiac risk factors must be excluded: transmural&#xD;
             myocardial infarction (MI) within prior 6 months, severe/unstable angina pectoris,&#xD;
             coronary/peripheral artery bypass graft, cerebrovascular accident or transient&#xD;
             ischemic attack (TIA) or seizure disorder within 6 months prior to study drug&#xD;
             administration. In addition, patients with New York Heart Association (NYHA) class III&#xD;
             or IV heart failure will be excluded&#xD;
&#xD;
          -  Patients requiring treatment with other anti-depressive medications including the&#xD;
             selective and non-selective monoamine oxidase (MAO) inhibitors (including linezolid),&#xD;
             5-hydroxytryptamine (5-HT) receptor agonists (triptans), tryptophan or&#xD;
             antidopaminergic agents (anti-psychotics, metoclopramide, promethazine, haloperidol)&#xD;
&#xD;
          -  Patients requiring prolonged treatment with fluconazole, voriconazole, or&#xD;
             posaconazole. Use of isavuconazonium sulfate, liposomal amphotericin, are&#xD;
             echinocandins are permitted&#xD;
&#xD;
          -  Prior treatment with clofarabine within 6 months or history of clofarabine-induced&#xD;
             liver dysfunction&#xD;
&#xD;
          -  History of hypersensitivity to sertraline&#xD;
&#xD;
          -  Patients taking sertraline at the time of study entry will not be eligible for the&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisa Olmos, RN</last_name>
    <phone>212-342-5162</phone>
    <email>cancerclinicaltrials@cumc.columbia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ryan Shelton, BS</last_name>
    <email>rs3323@cumc.columbia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Johns Hopkins University Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivana Gojo</last_name>
      <phone>410-502-7726</phone>
      <email>igojo1@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Ivana Gojo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Katsigeorgis, MS</last_name>
      <email>mk3941@cumc.columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ryan Shelton, BS</last_name>
      <email>rs3323@cumc.columbia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mark Frattini, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel J Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 1, 2016</study_first_submitted>
  <study_first_submitted_qc>September 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2016</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Daniel Lee</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Leukemia</keyword>
  <keyword>Sertraline</keyword>
  <keyword>Cytosine Arabinoside</keyword>
  <keyword>Relapsed AML</keyword>
  <keyword>Refractory AML</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Sertraline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

